Clinical Trials Browser

pirtobrutinib × Clear all

NCT06973187 2026-05-27

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07218341 2026-05-22

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 4 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06588478 2026-05-19

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04662255 2026-05-15

BRUIN-MCL-321

Phase 3 Active not recruiting

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04623541 2026-05-05

EPCORE™ CLL-1

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05529069 2026-05-05

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia

NCT04666038 2026-04-24

BRUIN CLL-321

Phase 3 Active not recruiting

238 enrolled 17 charts 1 FDA

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06263491 2026-04-23

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT07548450 2026-04-23

MPOWER

Phase 2 Not yet recruiting

Waldenstrom Macroglobulinemia

NCT06948786 2026-04-22

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Phase 2 Recruiting

Lymphoma, Follicular

NCT05254743 2026-04-20

BRUIN-CLL-314

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06252675 2026-04-20

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT07162181 2026-04-17

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06522386 2026-04-16

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT07516093 2026-04-08

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Phase 3 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06553872 2026-03-31

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT07428707 2026-03-13

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Phase EARLY_PHASE1 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06876649 2026-03-02

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Phase 4 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06876662 2026-03-02

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Phase 4 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05990465 2026-02-23

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Phase 1 Recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06466122 2026-02-19

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05677919 2026-02-12

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04849416 2026-02-06

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

Phase 2 Completed

87 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04965493 2026-01-29

BRUIN CLL-322

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 2 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05023980 2026-01-22

BRUIN CLL-313

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06333262 2026-01-21

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07285590 2025-12-16

IMCL-2023

Phase 2 Recruiting

Lymphoma, Lymphoma, Mantle-Cell

NCT05317936 2025-12-15

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06390956 2025-12-04

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

Phase 2 Recruiting

Lymphoma, B-Cell, Marginal Zone

NCT07255963 2025-12-01

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Phase 2 Recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT07231952 2025-11-17

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06967610 2025-11-06

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07207785 2025-10-06

FIL_PUMA

Phase 2 Not yet recruiting

Lymphoma, Mantle-Cell

NCT06812715 2025-08-06

PIPOZA

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06839872 2025-06-05

BOSS

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05734495 2025-05-11

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Approved for marketing

LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05833763 2024-01-08

GOlDiLOX

Phase 2 Recruiting

Lymphoma, Mantle-Cell